This review is of the BLAST study - Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
Independent commentary is provided by Dr. David Yeung, a haematologist and Bone marrow transplant physician at the Royal Adelaide Hospital and Research Fellow at the South Australian Health and Medical Research Institute.
Please login below to download this issue (PDF)